Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.

Adalimumab, etanercept and ustekinumab all offer some benefits for plaque psoriasis in children and young people but their cost per QALY is highly uncertain.

http://ift.tt/2yHhPOG